Diazepam (Diastat) vs Stiripentol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Diazepam (Diastat)

Marketed by Bausch Health

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Stiripentol

Marketed by Biocodex

Approved in Epilepsysmall molecule
Weak signal

NCT07176832 · Phase 1 · completed

This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDiazepam (Diastat)Stiripentol
Seizure frequency, % change—Not reported—Not reported
50% responder rate—Not reported—Not reported
Seizure freedom—Not reported—Not reported

Seizure frequency, % change

Diazepam (Diastat)
—Not reported
Stiripentol
—Not reported

50% responder rate

Diazepam (Diastat)
—Not reported
Stiripentol
—Not reported

Seizure freedom

Diazepam (Diastat)
—Not reported
Stiripentol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Stiripentol: no structured comparison results are available for Epilepsy.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Diazepam (Diastat): 2 of 4 rows · Stiripentol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDiazepam (Diastat)
Dropout rate
—
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
Discontinued due to AEs
—
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
Serious AEs
0%
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2
Most frequent reported AEs
somnolence 20.7%
dizziness 6.9%
headache 6.9%
NCT03953820 · Phase 1/2 · registry result, not featured evidence · Epilepsy · phase 1/2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Diastat)'s landscape · Stiripentol's landscape